A randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) amyloidosis.
A phase II open-label randomized study of dietary supplement with epigallocatechin gallate (EGCG) to improve cardiac dysfunction in patients with AL amyloidosis who do not require chemotherapy (EpiCardiAL).
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed/Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment.
The effect of Diflunisal on familial amyloidosis (IND 68092): A randomized, double-blind, placebo-controlled, international multi-center trial of diflunisal. A randomized, double-blind, placebo-controlled, international multi-center trial of diflunisal on neurologic disease progression in 200 familial amyloid subjects.
A single center, twelve-month, open-label, prospective study followed by a six-month withdrawal period to evaluate the efficacy, tolerability, safety and pharmacokinetics (PK) of dosycycline in combination with tauroursodeosycholic acid (TUDCA) in adults with transthyretin amyloidosis (ATTR).
SINDROME AUTOINFIAMMATORIA TRAPS
An open-label, multicenter, efficacy and safety study of 4-month canakinumab treatment with 6-month follow-up in patients with active recurrent or chronic TNF-receptor associated periodic syndrome (TRAPS).